Regulatory

>

Latest News

FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma

February 14th 2025

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation.

FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy
FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy

February 13th 2025

Navigating the EU’s Joint Clinical Assessment
Navigating the EU’s Joint Clinical Assessment

February 13th 2025

FDA Approves SpringWorks Therapeutics’ Gomekli for Neurofibromatosis Type 1, Symptomatic Plexiform Neurofibromas
FDA Approves SpringWorks Therapeutics’ Gomekli for Neurofibromatosis Type 1, Symptomatic Plexiform Neurofibromas

February 12th 2025

Monica Martin de Bustamante
Changing Political Winds and the IRA: Q&A with Monica Martin de Bustamante

February 12th 2025

More News